XO­MA to buy Kin­nate; A pain biotech’s small IPO

Plus, news about Blue­print Med­i­cines, So­sei Group and Pox­el:

XO­MA to buy Kin­nate Bio­phar­ma: The biotech roy­al­ty ag­gre­ga­tor said it would pay $2.33 per share in cash for the clin­i­cal-stage on­col­o­gy com­pa­ny. An ad­di­tion­al 25 cents per share could be added, as well as rights for Kin­nate share­hold­ers to re­ceive pro­ceeds if XO­MA of­floads as­sets. Kin­nate’s shares $KNTE were up about 10% in pre­mar­ket trad­ing on Fri­day. Last Sep­tem­ber, Kin­nate laid off most em­ploy­ees, re­duced its pipeline and was “sep­a­rat­ing” from all staffers at its Chi­nese sub­sidiary. — Kyle LaHu­cik

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER